MetaCap

Iambic Therapeutics Stock Forecast

NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

13.11-1.15 (-8.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IAM analyst consensus

Consensus (4 analysts)

strong_buy

Avg. price target

$27.25+107.86%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $22.00High $35.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

What analysts say

According to 4 Wall Street analysts covering Iambic Therapeutics (2026-11-21), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $27.25, with a high estimate of $35.00 and a low estimate of $22.00. The average target implies upside of 107.9% from the current price of $13.11.

The spread between the highest and lowest targets is 59.1%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IAM.

Summary generated from market data by MetaCap's automated system. Methodology

Rating distribution

Iambic Therapeutics analyst rating distribution
RatingAnalystsShare
Strong buy125%
Buy375%
Hold00%
Sell00%
Strong sell00%

Ratings as of 2026-11-21.

Price target scenarios

Price targets versus the current price
TargetPricevs. current
Low target$22.00+67.81%
Average target$27.25+107.86%
High target$35.00+166.97%

How analysts view Iambic Therapeutics's peers

Peer analyst targets
CompanyConsensusPriceAvg. targetImplied move
SRZNstrong_buy28.46$63.50+123.12%
CGEMstrong_buy8.89$34.27+285.49%
FDMTstrong_buy10.23$28.09+174.58%
ENTXstrong_buy3.31$9.75+195.01%
DBVTbuy9.02$36.54+305.10%
ATTOstrong_buy15.10$43.20+186.09%

Related